Risks for multidrug-resistant pathogens in the ICU
- PMID: 25188366
- DOI: 10.1097/MCC.0000000000000124
Risks for multidrug-resistant pathogens in the ICU
Abstract
Purpose of review: The impact of multidrug-resistant organisms (MDROs) is rising and often underestimated. The epidemiology of MDROs is extremely complex and multifactorial. There is increasing antibiotic resistance, mainly related to antibiotic pressure and patients' characteristics.
Recent findings: Emphasis on MDRO epidemiology is needed to better understand current strategies of prevention and management. Among them, antibiotic stewardship has been one of the most successful strategies. It is important to note that there is a controversial issue when considering community and healthcare-related infections. In addition, different strategies have been determined to find the impact and optimal use of recently launched antibiotics for MDRO treatment.
Summary: Infections with MDROs can prolong hospital stay, promote antibiotic use and prolong duration of mechanical ventilation. Some points should be further explored in clinical research such as the heterogeneity of healthcare-associated pneumonia and the need of new drug development. Resistance to non fermentative Gram-negative bacilli, rising minimum inhibitory concentration in methicillin-resistant Staphylococcus aureus and spread of MDROs in patients without known risk factors suggest a review of guideline validation, taking into account ecology and severity of patient illness to provide timely and appropriate empiric therapy.
Similar articles
-
Value of American Thoracic Society guidelines in predicting infection or colonization with multidrug-resistant organisms in critically ill patients.PLoS One. 2014 Mar 19;9(3):e89687. doi: 10.1371/journal.pone.0089687. eCollection 2014. PLoS One. 2014. PMID: 24647408 Free PMC article. Clinical Trial.
-
Advances in the management of pneumonia in the intensive care unit: review of current thinking.Clin Microbiol Infect. 2005 Oct;11 Suppl 5:30-8. doi: 10.1111/j.1469-0691.2005.01241.x. Clin Microbiol Infect. 2005. PMID: 16138817 Review.
-
Infection prevention control bundle of multidrug-resistant Acinetobacter baumannii and methicillin-resistant Staphylococcus aureus: which one is more important?Infect Control Hosp Epidemiol. 2014 Feb;35(2):207-8. doi: 10.1086/674865. Infect Control Hosp Epidemiol. 2014. PMID: 24442090 No abstract available.
-
Practices to prevent multidrug-resistant Acinetobacter baumannii and methicillin-resistant Staphylococcus aureus in Thailand: a national survey.Am J Infect Control. 2013 May;41(5):416-21. doi: 10.1016/j.ajic.2012.05.011. Epub 2012 Oct 23. Am J Infect Control. 2013. PMID: 23098775
-
Antibiotic considerations in the treatment of multidrug-resistant (MDR) pathogens: a case-based review.J Hosp Med. 2009 Jul;4(6):E8-15. doi: 10.1002/jhm.505. J Hosp Med. 2009. PMID: 19670375 Review.
Cited by
-
Real-Time TDM-Based Expert Clinical Pharmacological Advice Program for Attaining Aggressive Pharmacokinetic/Pharmacodynamic Target of Continuous Infusion Meropenem in the Treatment of Critically Ill Patients with Documented Gram-Negative Infections Undergoing Continuous Veno-Venous Hemodiafiltration.Antibiotics (Basel). 2023 Oct 10;12(10):1524. doi: 10.3390/antibiotics12101524. Antibiotics (Basel). 2023. PMID: 37887225 Free PMC article.
-
Burden of severe infections due to carbapenem-resistant pathogens in intensive care unit.World J Clin Cases. 2023 May 6;11(13):2874-2889. doi: 10.12998/wjcc.v11.i13.2874. World J Clin Cases. 2023. PMID: 37215420 Free PMC article. Review.
-
Retrospective analysis of drug resistance characteristics and infection related risk factors of multidrug-resistant organisms (MDROs) isolated from the orthopedics department of a tertiary hospital.Sci Rep. 2023 Feb 7;13(1):2199. doi: 10.1038/s41598-023-28270-3. Sci Rep. 2023. PMID: 36750600 Free PMC article.
-
Clinical management of cUTI, cIAI, and HABP/VABP attributable to carbapenem-resistant Gram-negative infections in Spain.Rev Esp Quimioter. 2021 Dec;34(6):639-650. doi: 10.37201/req/096.2021. Epub 2021 Nov 22. Rev Esp Quimioter. 2021. PMID: 34806858 Free PMC article.
-
Association between tocilizumab and emerging multidrug-resistant organisms in critically ill patients with COVID-19: A multicenter, retrospective cohort study.BMC Infect Dis. 2021 Nov 1;21(1):1127. doi: 10.1186/s12879-021-06813-1. BMC Infect Dis. 2021. PMID: 34724920 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials
